Drug Profile


Alternative Names: Amatine; Gudon; Gutron; Metligine; Midodrine HCl; Midon; ProAmatine; ST 1085; TS 701

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator GE Healthcare
  • Developer Myungmoon Pharm; Shire; Shire Pharmaceuticals Group; Taisho Pharmaceutical
  • Class Antihypotensives; Ethanolamines; Small molecules
  • Mechanism of Action Alpha adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Orthostatic hypotension; Urinary incontinence
  • No development reported Chronic fatigue syndrome

Most Recent Events

  • 29 Mar 2012 Shire initiates two postmarketing clinical trials for Orthostatic hypotension
  • 02 Dec 2011 Shire and the US FDA Center for Drug Evaluation and Research reach an agreement to conduct two postmarketing clinical trials for Orthostatic hypotension
  • 22 Sep 2011 Shire & the US FDA continue to discuss the final approval of midodrine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top